A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results

• Published in: HIV clinical trials Vol. 13; no. 3; p. 119
• Main Authors: Kozal, Michael J, Lupo, Sergio, DeJesus, Edwin, Molina, Jean-Michel, McDonald, Cheryl, Raffi, Francois, Benetucci, Jorge, Mancini, Marco, Yang, Rong, Wirtz, Victoria, Percival, Lisa, Zhang, Jenny, Zhu, Li, Arikan, Dilek, Farajallah, Awny, Nguyen, Bach-Yen, Leavitt, Randi, McGrath, Donnie, Lataillade, Max, The Spartan Study Team
• Format: Journal Article
• Language: English
• Published: England 01.05.2012
• Subjects: Adult; Anti-HIV Agents - administration & dosage; Atazanavir Sulfate; CD4 Lymphocyte Count; DNA, Viral - blood; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections - drug therapy; HIV Infections - immunology; HIV Infections - virology; Humans; Lipids - blood; Male; Nucleosides - therapeutic use; Oligopeptides - administration & dosage; Pyridines - administration & dosage; Pyrrolidinones - administration & dosage; Raltegravir Potassium; Ritonavir - therapeutic use
• ISSN: 1528-4336
• DOI: 10.1310/hct1303-119

Nucleoside and ritonavir (RTV) toxicities have led to increased interest in nucleoside reverse transcriptase inhibitors (NRTIs) and RTV-sparing antiretroviral regimens. SPARTAN was a multicenter, randomized, open-label, noncomparative pilot study evaluating the efficacy, safety, and resistance profi...